Receptor binding
Peptides can act as molecular signals, binding to specific receptors on or within cells and initiating a biological response.
THE SCIENCE BEHIND AERVYN
Science
Peptides,explained.
Peptide science can become complicated quickly. Aervyn Science makes the biology, mechanisms and evidence easier to navigate without oversimplifying what researchers actually know.
FIRST, THE FUNDAMENTALS
What is a peptide?
Proteins and peptides are both built from amino acids. Peptides generally contain shorter sequences, and their precise sequence and three-dimensional structure influence how they interact with biological systems. Many occur naturally within the body and participate in signalling between cells, tissues and organs. Synthetic peptides allow researchers to investigate these biological signals in controlled settings.
MECHANISMS01 02 03 04
How peptides work
Small molecules can act as highly specific signals. Researchers study how sequence, receptor binding and downstream cellular pathways may influence biological processes over time.
Cell-signalling pathways
Once a receptor is engaged, downstream pathways can alter gene expression, metabolism, inflammatory signalling or other cellular activity.
Tissue and repair signalling
Some research focuses on collagen production, vascular signalling and extracellular-matrix remodelling relevant to tissue biology.
Mitochondrial and metabolic signalling
Other compounds are investigated for their relationship with mitochondrial function, cellular energy production and metabolic adaptation.
EVIDENCE LEVELSA B C D
A possible explanation is not the same as proof.
A product may have a sensible explanation for how it could work, while the real-world information is still limited. These levels show how much information is available, so you can understand the difference between established findings, early signals and ideas that still need more checking.
Strong evidence from studies in people
Several well-designed studies in people or established evidence for a defined use.
Some evidence from studies in people
Useful information from people, but with important gaps, limits or a smaller evidence base.
Early or mixed information
A small amount of information from people alongside early laboratory or animal studies.
Early laboratory or animal information
Information mainly comes from laboratory models, animal studies or very limited studies in people.
SCIENCE CATEGORY INTRODUCTIONS
Explore the science by category.
Begin with a research category, then open an individual product to read the complete detail. Every category and product remains closed until selected.
04 PRODUCTSRecovery & repair
Products associated with tissue response, connective tissue and recovery pathways.
04 PRODUCTS
Recovery & repair
Products associated with tissue response, connective tissue and recovery pathways.
Grade CWolverine™
BPC-157 20 mg + TB-500 20 mg
- Reference amount
- 0.25 to 0.5 mg of each ingredient
Grade C
Wolverine™
BPC-157 20 mg + TB-500 20 mg
- Frequency
- Daily source-reported reference
- Cycle
- 4 to 6 weeks, followed by 2 to 4 weeks off
Product overview
Wolverine combines equal amounts of BPC-157 and TB-500 in one pre-filled 3 mL pen. The two compounds are commonly discussed together in experimental soft-tissue, tendon, ligament, mobility and recovery research.
Biological context
BPC-157 is investigated for signalling associated with tissue response, vascular biology and the gastrointestinal barrier. TB-500 is a synthetic fragment associated with thymosin beta-4 research and is studied for cell migration, actin regulation and tissue remodelling.
Research context
The guide reports a combined reference of 0.25 to 0.5 mg of each ingredient daily. It describes the blend as a commonly discussed experimental stack rather than an established treatment.
Evidence context
Grade C
Published evidence is predominantly preclinical. Findings from laboratory or animal models do not establish safety or effectiveness in people, and evidence for the fixed combination is more limited than evidence for either ingredient considered separately.
Limitations
A total blend amount does not reveal the amount of each active unless the 1:1 composition is considered. Individual ingredient data cannot confirm the effect, safety or suitability of the combined pen.
Research focus
Connective tissue · Tendon and ligament biology · Cell migration · Recovery pathways
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Headache, Fatigue, Nausea, Dizziness.
Grade DKLOW™
GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg
- Reference amount
- Ingredient-specific references only
Grade D
KLOW™
GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg
- Frequency
- Not established for the fixed blend
- Cycle
- Component references span 4 to 8 weeks
Product overview
KLOW combines GHK-Cu, BPC-157, TB-500 and KPV in a broad experimental formulation spanning tissue response, extracellular matrix, skin biology and barrier-signalling research.
Biological context
The four ingredients are investigated through different pathways. GHK-Cu relates to copper and matrix signalling, BPC-157 and TB-500 to experimental tissue-response pathways, and KPV to inflammatory and barrier-related signalling.
Research context
The guide discusses each component separately. It reports 1 to 2 mg daily for injectable GHK-Cu, 0.25 to 0.5 mg daily for BPC-157, 2 to 5 mg weekly for TB-500 and 0.25 to 1 mg daily for KPV.
Evidence context
Grade D
The combined formulation has no established clinical evidence base. Evidence for individual components is uneven, predominantly preclinical and cannot be assumed to describe the blend.
Limitations
Four ingredient-specific ranges cannot be combined into one validated protocol. Total milligrams do not communicate the dose of each component without the formulation breakdown.
Research focus
Tissue response · Barrier signalling · Extracellular matrix · Skin biology
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Headache, Fatigue, Nausea, Skin irritation, Dizziness.
Grade DBPC-157
BPC-157 10 mg
- Reference amount
- 0.25 to 0.5 mg
Grade D
BPC-157
BPC-157 10 mg
- Frequency
- Twice daily source reference
- Cycle
- 4 to 6 weeks in the guide
Product overview
BPC-157 is included in the guide under recovery & repair. The reference focuses on tissue response, gastrointestinal barrier and vascular-signalling research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A synthetic gastric-peptide fragment investigated in laboratory and animal models for tissue response, angiogenic signalling and gastrointestinal protection.
Research context
The guide records 0.25 to 0.5 mg with twice daily source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade D
Grade D, preclinical evidence. Regulatory reference in the guide: not approved for human therapeutic use. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Tissue response · Gastrointestinal barrier and vascular-signalling research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Headache, Nausea, Dizziness, Fatigue.
Grade DTB-500
TB-500 10 mg
- Reference amount
- 2 to 5 mg
Grade D
TB-500
TB-500 10 mg
- Frequency
- Twice weekly source reference
- Cycle
- 4 to 6 weeks in the guide
Product overview
TB-500 is included in the guide under recovery & repair. The reference focuses on actin regulation, cell migration and tissue-remodelling research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A synthetic thymosin beta-4 fragment investigated for cell migration, actin dynamics, angiogenic signalling and tissue remodelling.
Research context
The guide records 2 to 5 mg with twice weekly source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade D
Grade D, preclinical evidence. Regulatory reference in the guide: not approved for human therapeutic use. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Actin regulation · Cell migration and tissue-remodelling research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Headache, Fatigue, Nausea, Dizziness.
04 PRODUCTSLongevity & energy
Mitochondrial and cellular-energy research areas with uncertainty made clear.
04 PRODUCTS
Longevity & energy
Mitochondrial and cellular-energy research areas with uncertainty made clear.
Grade CMOTS-C
MOTS-C 60 mg
- Reference amount
- 5 to 10 mg
Grade C
MOTS-C
MOTS-C 60 mg
- Frequency
- Weekly source-reported reference
- Cycle
- 4 to 8 weeks, followed by 2 to 4 weeks off
Product overview
MOTS-C is a small peptide encoded within mitochondrial DNA. Research explores its relationship with cellular energy sensing, glucose and lipid metabolism, metabolic flexibility and adaptation to physical stress.
Biological context
Experimental work links MOTS-C with metabolic signalling pathways that help cells respond to energy demand. Proposed activity includes communication between mitochondria and the cell nucleus, but the biological picture remains incomplete.
Research context
The guide places MOTS-C in both metabolic-health and longevity research and reports a 5 to 10 mg weekly reference.
Evidence context
Grade C
Human evidence remains limited and exploratory. Much of the interest comes from laboratory and animal work, which should not be treated as proof of clinical benefit.
Limitations
The effects of formulation, population, route and long-term exposure are not established. A mitochondrial mechanism does not itself demonstrate improved energy, performance or longevity in people.
Research focus
Mitochondrial signalling · Cellular energy · Metabolic adaptation · Exercise-related pathways
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Headache, Fatigue, Dizziness, Nausea.
Grade DNAD+
Nicotinamide adenine dinucleotide 500 mg
- Reference amount
- 25 to 100 mg subcutaneous source reference
Grade D
NAD+
Nicotinamide adenine dinucleotide 500 mg
- Frequency
- Daily source-reported reference
- Cycle
- 4 to 12 weeks, followed by 2 to 4 weeks off
Product overview
NAD+ is a coenzyme present in cells throughout the body. It is essential to redox reactions, cellular energy transfer, DNA-repair signalling and multiple enzyme systems associated with mitochondrial function and cellular ageing.
Biological context
NAD+ accepts and transfers electrons during energy metabolism and acts as a substrate for enzymes including sirtuins and PARPs. Levels and effects vary by tissue, metabolic state, route and formulation.
Research context
The guide separates routes: 250 to 1,000 mg intravenously, 25 to 100 mg daily subcutaneously and 250 to 500 mg daily orally. Route-specific figures must not be treated as interchangeable.
Evidence context
Grade D
Evidence varies substantially by route, population and outcome. Biochemical plausibility and changes in biomarkers do not establish a meaningful benefit from this presentation.
Limitations
Absorption, metabolism and tolerability differ between intravenous, subcutaneous and oral formats. The guide does not validate this particular pre-filled pen or establish long-term outcomes.
Research focus
Redox biology · Cellular energy · DNA-repair signalling · Mitochondrial function
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Flushing, Nausea, Headache, Chest tightness, Abdominal discomfort.
Grade DEpitalon
Epitalon 50 mg
- Reference amount
- 5 to 10 mg
Grade D
Epitalon
Epitalon 50 mg
- Frequency
- Daily source reference
- Cycle
- 10 to 20 days in the guide
Product overview
Epitalon is included in the guide under longevity & energy. The reference focuses on telomere, circadian and healthy-ageing research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A synthetic tetrapeptide investigated for telomerase-related, pineal and circadian pathways, largely in preclinical and limited human contexts.
Research context
The guide records 5 to 10 mg with daily source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade D
Grade D, predominantly preclinical evidence. Regulatory reference in the guide: not broadly approved. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Telomere · Circadian and healthy-ageing research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Headache, Fatigue, Dizziness, Sleep changes.
Grade DFOXO4-DRI
FOXO4-DRI 10 mg
- Reference amount
- No established human amount
Grade D
FOXO4-DRI
FOXO4-DRI 10 mg
- Frequency
- Every other day preclinical reference
- Cycle
- Three to six research doses in the guide
Product overview
FOXO4-DRI is included in the guide under longevity & energy. The reference focuses on senescence and foxo4-p53 interaction research and distinguishes biological rationale from demonstrated outcomes.
Biological context
An experimental D-retro-inverso peptide designed to disrupt FOXO4 and p53 interaction in senescent-cell models.
Research context
The guide records No established human amount with every other day preclinical reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade D
Grade D, preclinical evidence. Regulatory reference in the guide: research only. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Senescence and FOXO4-p53 interaction research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Human safety profile not established, Unknown immune effects, Unknown long-term effects.
02 PRODUCTSSkin & beauty
Collagen, skin and hair-follicle research in a consistent product format.
02 PRODUCTS
Skin & beauty
Collagen, skin and hair-follicle research in a consistent product format.
Grade CGHK-Cu
GHK-Cu 100 mg
- Reference amount
- 1 to 2 mg injectable research reference
Grade C
GHK-Cu
GHK-Cu 100 mg
- Frequency
- Daily source-reported reference
- Cycle
- 4 to 8 weeks, followed by 2 to 4 weeks off
Product overview
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma and other body fluids. It is studied in relation to extracellular-matrix renewal, collagen and elastin biology, wound response, skin quality and hair follicles.
Biological context
GHK binds copper ions and is investigated for its influence on gene expression, antioxidant activity, inflammatory signalling and matrix-remodelling enzymes. Activity can differ substantially between topical and injectable research contexts.
Research context
The guide reports an injectable research reference of 1 to 2 mg daily and separately notes topical concentrations of 1 to 5% once or twice daily.
Evidence context
Grade C
Research includes laboratory, topical, cosmetic and limited human contexts. The most established interest is topical. Results are route and formulation specific and cannot be generalised to this presentation.
Limitations
Topical observations do not validate an injectable outcome. Copper exposure, formulation quality and individual sensitivity are relevant uncertainties.
Research focus
Collagen and elastin biology · Skin quality · Wound response · Hair follicles
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Skin irritation, Headache, Nausea, Flushing.
Grade DGlow™
GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg
- Reference amount
- Ingredient-specific references only
Grade D
Glow™
GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg
- Frequency
- Not established for the fixed blend
- Cycle
- Component references span 4 to 8 weeks
Product overview
Glow combines GHK-Cu, BPC-157 and TB-500 in a single research formulation. Its ingredients span copper-peptide, tissue-response, extracellular-matrix and remodelling research.
Biological context
GHK-Cu is investigated for copper transport, collagen and matrix signalling. BPC-157 and TB-500 are studied experimentally for tissue response, vascular signalling, cell migration and actin regulation. A combined mechanism has not been clinically established.
Research context
The guide discusses all three components separately. It reports 1 to 2 mg daily for injectable GHK-Cu, 0.25 to 0.5 mg daily for BPC-157 and 2 to 5 mg weekly for TB-500.
Evidence context
Grade D
Evidence differs for each component and is largely preclinical for the combined formulation. The guide does not provide evidence for Glow as a fixed blend.
Limitations
Ingredient ranges cannot be added together or converted into a validated combined regimen. Differences in component strength mean a total milligram amount is not an equal dose of each ingredient.
Research focus
Skin biology · Collagen signalling · Extracellular matrix · Tissue remodelling
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Skin irritation, Headache, Fatigue, Nausea, Dizziness.
05 PRODUCTSMetabolic & weight
Investigational compounds associated with appetite and metabolic signalling.
05 PRODUCTS
Metabolic & weight
Investigational compounds associated with appetite and metabolic signalling.
Grade DR3T
R3T 40 mg
- Reference amount
- 1 to 12 mg escalation range
Grade D
R3T
R3T 40 mg
- Frequency
- Weekly source-reported research reference
- Cycle
- 24 to 48 weeks or longer in studies
Product overview
R3T is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. It is being studied in controlled clinical programmes for weight, appetite and wider metabolic outcomes.
Biological context
Its triple-agonist design combines incretin signalling with glucagon-receptor activity. Researchers are examining how this may affect appetite, energy balance, glucose regulation and body weight.
Research context
The guide reports a 1 to 12 mg weekly escalation range and notes study periods of 24 to 48 weeks or longer. These figures describe research, not an approved commercial regimen.
Evidence context
Grade D
Human clinical-trial evidence is developing, but findings relate to the studied medicine, manufacturing controls, eligibility criteria and monitored regimens. They do not establish equivalence with a separate presentation.
Limitations
R3T remains investigational and has no standard cycling model. Trial averages cannot predict individual response, and dose escalation can materially affect tolerability.
Research focus
GIP, GLP-1 and glucagon signalling · Appetite pathways · Weight outcomes · Metabolic control
Considerations
Gastrointestinal effects, dehydration, gallbladder or pancreatic concerns, glucose changes and heart-rate increases require appropriate medical oversight. Pen strength is not a dose recommendation.
Potential side effects
Nausea, Vomiting, Diarrhoea, Constipation, Reduced appetite, Increased heart rate.
Grade ASemaglutide
Semaglutide 10 mg
- Reference amount
- 0.25 to 2.4 mg
Grade A
Semaglutide
Semaglutide 10 mg
- Frequency
- Weekly source-reported reference
- Cycle
- Long-term clinical use where authorised
Product overview
Semaglutide is included in the guide under metabolic & weight. The reference focuses on glp-1 signalling, appetite and metabolic outcomes and distinguishes biological rationale from demonstrated outcomes.
Biological context
A long-acting GLP-1 receptor agonist studied for glucose-dependent insulin signalling, appetite regulation and gastric emptying.
Research context
The guide records 0.25 to 2.4 mg with weekly source-reported reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade A
Grade A, strong human evidence. Regulatory reference in the guide: approved medicines exist for defined indications. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
GLP-1 signalling · Appetite and metabolic outcomes
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Nausea, Vomiting, Diarrhoea, Constipation, Abdominal discomfort.
Grade ATirzepatide
Tirzepatide 30 mg
- Reference amount
- 2.5 to 15 mg
Grade A
Tirzepatide
Tirzepatide 30 mg
- Frequency
- Weekly source-reported reference
- Cycle
- Long-term clinical use where authorised
Product overview
Tirzepatide is included in the guide under metabolic & weight. The reference focuses on gip and glp-1 signalling, appetite and metabolic outcomes and distinguishes biological rationale from demonstrated outcomes.
Biological context
A dual GIP and GLP-1 receptor agonist studied for glucose regulation, appetite and body-weight outcomes.
Research context
The guide records 2.5 to 15 mg with weekly source-reported reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade A
Grade A, strong human evidence. Regulatory reference in the guide: approved medicines exist for defined indications. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
GIP and GLP-1 signalling · Appetite and metabolic outcomes
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Nausea, Vomiting, Diarrhoea, Constipation, Reduced appetite.
Grade ALiraglutide
Liraglutide 18 mg
- Reference amount
- 0.6 to 3 mg
Grade A
Liraglutide
Liraglutide 18 mg
- Frequency
- Daily source-reported reference
- Cycle
- Long-term clinical use where authorised
Product overview
Liraglutide is included in the guide under metabolic & weight. The reference focuses on glp-1 signalling, glucose control and weight research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A daily GLP-1 receptor agonist studied for glycaemic control, appetite regulation and cardiovascular outcomes in defined populations.
Research context
The guide records 0.6 to 3 mg with daily source-reported reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade A
Grade A, strong human evidence. Regulatory reference in the guide: approved medicines exist for defined indications. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
GLP-1 signalling · Glucose control and weight research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Nausea, Diarrhoea, Constipation, Vomiting, Injection-site reaction.
Grade BCagriSema
Cagrilintide + semaglutide 20 mg
- Reference amount
- Escalating study-defined combination amounts
Grade B
CagriSema
Cagrilintide + semaglutide 20 mg
- Frequency
- Weekly research reference
- Cycle
- Study-defined duration
Product overview
CagriSema is included in the guide under metabolic & weight. The reference focuses on amylin and glp-1 signalling in metabolic research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A fixed investigational combination of an amylin analogue with a GLP-1 receptor agonist.
Research context
The guide records Escalating study-defined combination amounts with weekly research reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade B
Grade B, moderate developing human evidence. Regulatory reference in the guide: late-stage investigational combination. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Amylin and GLP-1 signalling in metabolic research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Nausea, Vomiting, Constipation, Diarrhoea, Reduced appetite.
06 PRODUCTSGrowth & body
Experimental GH-axis and body-composition research products.
06 PRODUCTS
Growth & body
Experimental GH-axis and body-composition research products.
Grade ATesamorelin
Tesamorelin 20 mg
- Reference amount
- 1.28 to 2 mg
Grade A
Tesamorelin
Tesamorelin 20 mg
- Frequency
- Daily source-reported reference
- Cycle
- 12 weeks or longer, goal-dependent
Product overview
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. It is studied in defined clinical contexts for its effect on growth-hormone signalling, IGF-1 and body composition, particularly visceral-fat outcomes.
Biological context
Tesamorelin stimulates pituitary GHRH receptors, increasing pulsatile growth-hormone release and downstream IGF-1 signalling. This pathway affects multiple tissues and requires careful monitoring.
Research context
The guide reports 1.28 to 2 mg daily over 12 weeks or longer, with duration dependent on the research goal. Approved use, where it exists, is narrow and product specific.
Evidence context
Grade A
Tesamorelin has human evidence in a specific medical context. That evidence does not transfer automatically to general weight management, performance, anti-ageing use or a different presentation.
Limitations
Changes in visceral fat or biomarkers do not establish broader health benefit. Product equivalence, long-term use and outcomes outside authorised populations are not established.
Research focus
GHRH signalling · Growth-hormone axis · IGF-1 · Visceral fat and body composition
Considerations
May affect glucose regulation, fluid balance and growth-factor pathways. Active malignancy, pituitary conditions, pregnancy and other contraindications require qualified clinical assessment.
Potential side effects
Injection-site reaction, Joint pain, Swelling, Muscle pain, Glucose changes, Tingling or numbness.
Grade CIpamorelin
Ipamorelin 10 mg
- Reference amount
- 0.2 to 0.3 mg
Grade C
Ipamorelin
Ipamorelin 10 mg
- Frequency
- Two to three times daily source reference
- Cycle
- 8 to 12 weeks in the guide
Product overview
Ipamorelin is included in the guide under growth & body. The reference focuses on growth-hormone secretagogue and igf-1 research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A ghrelin-receptor agonist studied for pulsatile growth-hormone release with comparatively limited activity at some other pituitary pathways.
Research context
The guide records 0.2 to 0.3 mg with two to three times daily source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade C
Grade C, early or mixed evidence. Regulatory reference in the guide: not approved for general therapeutic use. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Growth-hormone secretagogue and IGF-1 research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Headache, Flushing, Dizziness, Water retention, Injection-site reaction.
Grade CCJC-1295 no DAC
CJC-1295 no DAC 10 mg
- Reference amount
- 0.1 to 0.2 mg
Grade C
CJC-1295 no DAC
CJC-1295 no DAC 10 mg
- Frequency
- Two to three times daily source reference
- Cycle
- 8 to 12 weeks in the guide
Product overview
CJC-1295 no DAC is included in the guide under growth & body. The reference focuses on ghrh signalling and pulsatile growth-hormone research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A growth hormone-releasing hormone analogue studied for pituitary GH release and downstream IGF-1 signalling.
Research context
The guide records 0.1 to 0.2 mg with two to three times daily source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade C
Grade C, early or mixed evidence. Regulatory reference in the guide: compounding status varies by market. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
GHRH signalling and pulsatile growth-hormone research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Flushing, Headache, Dizziness, Water retention, Injection-site reaction.
Grade BSermorelin
Sermorelin 10 mg
- Reference amount
- 0.2 to 0.5 mg
Grade B
Sermorelin
Sermorelin 10 mg
- Frequency
- Daily, five days per week source reference
- Cycle
- 3 to 6 months in the guide
Product overview
Sermorelin is included in the guide under growth & body. The reference focuses on ghrh signalling and growth-hormone-axis research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A shortened GHRH analogue that stimulates pituitary growth-hormone release and downstream IGF-1 signalling.
Research context
The guide records 0.2 to 0.5 mg with daily, five days per week source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade B
Grade B, moderate human evidence. Regulatory reference in the guide: historical authorised use with current status varying. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
GHRH signalling and growth-hormone-axis research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Flushing, Headache, Dizziness, Sleepiness.
Grade BMK-677
Ibutamoren, oral small molecule
- Reference amount
- 10 to 25 mg
Grade B
MK-677
Ibutamoren, oral small molecule
- Frequency
- Daily oral source reference
- Cycle
- 8 to 16 weeks in the guide
Product overview
MK-677 is included in the guide under growth & body. The reference focuses on ghrelin-receptor, gh and igf-1 research and distinguishes biological rationale from demonstrated outcomes.
Biological context
An orally active ghrelin-receptor agonist. It is not a peptide and is studied for effects on GH, IGF-1, appetite and glucose handling.
Research context
The guide records 10 to 25 mg with daily oral source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade B
Grade B, moderate human evidence. Regulatory reference in the guide: research compound. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Ghrelin-receptor · GH and IGF-1 research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Increased appetite, Water retention, Tingling, Fatigue, Glucose changes.
Grade AHGH 191aa
Somatropin 191 amino acid sequence
- Reference amount
- Indication and product-specific
Grade A
HGH 191aa
Somatropin 191 amino acid sequence
- Frequency
- Daily clinical reference
- Cycle
- Clinician-directed only
Product overview
HGH 191aa is included in the guide under growth & body. The reference focuses on growth-hormone replacement and igf-1 research and distinguishes biological rationale from demonstrated outcomes.
Biological context
Recombinant human growth hormone acts at GH receptors and increases downstream IGF-1 signalling across multiple tissues.
Research context
The guide records Indication and product-specific with daily clinical reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade A
Grade A, strong human evidence. Regulatory reference in the guide: prescription-only approved medicines exist. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Growth-hormone replacement and IGF-1 research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Fluid retention, Joint pain, Tingling, Glucose changes, Headache.
04 PRODUCTSCognitive & neuro
Compounds studied in cognitive, neuroprotective and neuroregenerative contexts.
04 PRODUCTS
Cognitive & neuro
Compounds studied in cognitive, neuroprotective and neuroregenerative contexts.
Grade CSelank
Selank intranasal peptide
- Reference amount
- Intranasal milligram protocol
Grade C
Selank
Selank intranasal peptide
- Frequency
- Two to three times daily source reference
- Cycle
- 10 to 14 days in the guide
Product overview
Selank is included in the guide under cognitive & neuro. The reference focuses on anxiety, attention and neurotrophic-signalling research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A synthetic tuftsin-related peptide investigated for anxiolytic, cognitive and neurotrophic signalling, primarily through intranasal research.
Research context
The guide records Intranasal milligram protocol with two to three times daily source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade C
Grade C, early or mixed evidence. Regulatory reference in the guide: not broadly approved. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Anxiety · Attention and neurotrophic-signalling research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Nasal irritation, Headache, Fatigue, Taste disturbance, Dizziness.
Grade CSemax
Semax intranasal peptide
- Reference amount
- Intranasal milligram protocol
Grade C
Semax
Semax intranasal peptide
- Frequency
- Two to three times daily source reference
- Cycle
- 10 to 14 days in the guide
Product overview
Semax is included in the guide under cognitive & neuro. The reference focuses on cognition, neurotrophic factors and stroke research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A synthetic ACTH fragment investigated for BDNF and NGF-related signalling, cognition and neuroprotection.
Research context
The guide records Intranasal milligram protocol with two to three times daily source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade C
Grade C, early or mixed evidence. Regulatory reference in the guide: authorised in limited jurisdictions only. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Cognition · Neurotrophic factors and stroke research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Nasal irritation, Headache, Restlessness, Taste disturbance, Fatigue.
Grade BCerebrolysin
Porcine brain-derived peptide mixture
- Reference amount
- Product and indication-specific millilitres
Grade B
Cerebrolysin
Porcine brain-derived peptide mixture
- Frequency
- Daily IV or IM source reference
- Cycle
- 10 to 20 days in the guide
Product overview
Cerebrolysin is included in the guide under cognitive & neuro. The reference focuses on neuroregeneration, stroke and traumatic-brain-injury research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A complex peptide mixture investigated for neurotrophic and neuroprotective activity in neurological settings.
Research context
The guide records Product and indication-specific millilitres with daily iv or im source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade B
Grade B, moderate but mixed human evidence. Regulatory reference in the guide: authorised in some jurisdictions, not others. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Neuroregeneration · Stroke and traumatic-brain-injury research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Headache, Dizziness, Agitation, Sweating, Injection-related effects.
Grade DDihexa
Dihexa research compound
- Reference amount
- No established human amount
Grade D
Dihexa
Dihexa research compound
- Frequency
- Experimental reference only
- Cycle
- Not established
Product overview
Dihexa is included in the guide under cognitive & neuro. The reference focuses on hgf and met signalling in experimental cognition research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A small peptide-derived compound investigated preclinically for HGF and MET pathway activity and synaptogenesis.
Research context
The guide records No established human amount with experimental reference only. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade D
Grade D, preclinical evidence. Regulatory reference in the guide: research only. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
HGF and MET signalling in experimental cognition research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Human safety profile not established, Unknown long-term effects.
03 PRODUCTSHormones & sexual health
Products associated with reproductive signalling, fertility and sexual-health research.
03 PRODUCTS
Hormones & sexual health
Products associated with reproductive signalling, fertility and sexual-health research.
Grade APT-141
Bremelanotide 10 mg
- Reference amount
- 1.75 mg
Grade A
PT-141
Bremelanotide 10 mg
- Frequency
- As-needed source reference
- Cycle
- No routine cycle in authorised use
Product overview
PT-141 is included in the guide under hormones & sexual health. The reference focuses on central melanocortin signalling and sexual-health research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A melanocortin receptor agonist that acts centrally rather than through vascular PDE5 pathways.
Research context
The guide records 1.75 mg with as-needed source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade A
Grade A for an authorised formulation and indication. Regulatory reference in the guide: prescription medicine exists for a defined indication. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Central melanocortin signalling and sexual-health research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Nausea, Flushing, Headache, Injection-site reaction, Temporary blood-pressure increase.
Grade BGonadorelin
Gonadorelin 10 mg
- Reference amount
- Protocol-specific milligram amounts
Grade B
Gonadorelin
Gonadorelin 10 mg
- Frequency
- Two to three times weekly source reference
- Cycle
- Clinician-defined
Product overview
Gonadorelin is included in the guide under hormones & sexual health. The reference focuses on gnrh signalling, fertility and reproductive-axis research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A synthetic GnRH analogue that stimulates pituitary LH and FSH release when delivered in an appropriate pulsatile context.
Research context
The guide records Protocol-specific milligram amounts with two to three times weekly source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade B
Grade B, moderate human evidence. Regulatory reference in the guide: authorised uses and availability vary. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
GnRH signalling · Fertility and reproductive-axis research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Headache, Flushing, Injection-site reaction, Nausea, Hormonal changes.
Grade AHCG
Human chorionic gonadotropin
- Reference amount
- Indication and product-specific international units
Grade A
HCG
Human chorionic gonadotropin
- Frequency
- Two to three times weekly source reference
- Cycle
- Clinician-directed only
Product overview
HCG is included in the guide under hormones & sexual health. The reference focuses on lh-receptor signalling and fertility research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A glycoprotein hormone that acts at LH receptors and is used in authorised fertility and endocrine contexts.
Research context
The guide records Indication and product-specific international units with two to three times weekly source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade A
Grade A, strong human evidence. Regulatory reference in the guide: prescription-only approved medicines exist. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
LH-receptor signalling and fertility research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Headache, Mood changes, Fluid retention, Hormonal effects.
03 PRODUCTSImmune & gut
Compounds investigated in immune, antimicrobial and gastrointestinal barrier contexts.
03 PRODUCTS
Immune & gut
Compounds investigated in immune, antimicrobial and gastrointestinal barrier contexts.
Grade DKPV
KPV 10 mg
- Reference amount
- 0.25 to 1 mg
Grade D
KPV
KPV 10 mg
- Frequency
- Daily source reference
- Cycle
- Four to eight weeks in the guide
Product overview
KPV is included in the guide under immune & gut. The reference focuses on gut-barrier, melanocortin and inflammatory-signalling research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A short alpha-MSH-derived tripeptide investigated for MC1R-related, NF-kB and gastrointestinal barrier pathways.
Research context
The guide records 0.25 to 1 mg with daily source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade D
Grade D, preclinical evidence. Regulatory reference in the guide: research only. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Gut-barrier · Melanocortin and inflammatory-signalling research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Headache, Nausea, Fatigue, Dizziness.
Grade CLL-37
LL-37 10 mg
- Reference amount
- Guide-reported experimental amount
Grade C
LL-37
LL-37 10 mg
- Frequency
- Daily, five days per week source reference
- Cycle
- Three to six weeks in the guide
Product overview
LL-37 is included in the guide under immune & gut. The reference focuses on antimicrobial, innate-immune and wound-response research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A human cathelicidin peptide investigated for antimicrobial activity, innate immunity, inflammatory signalling and wound response.
Research context
The guide records Guide-reported experimental amount with daily, five days per week source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade C
Grade C, early or mixed evidence. Regulatory reference in the guide: research only. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
Antimicrobial · Innate-immune and wound-response research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Flu-like symptoms, Inflammatory flare, Fatigue, Headache.
Grade BThymosin Alpha-1
Thymosin Alpha-1 10 mg
- Reference amount
- 1.6 mg
Grade B
Thymosin Alpha-1
Thymosin Alpha-1 10 mg
- Frequency
- Twice weekly source reference
- Cycle
- Six to twelve weeks in the guide
Product overview
Thymosin Alpha-1 is included in the guide under immune & gut. The reference focuses on t-cell, toll-like-receptor and immune-modulation research and distinguishes biological rationale from demonstrated outcomes.
Biological context
A thymic peptide investigated for dendritic-cell, T-cell and toll-like-receptor signalling in immune contexts.
Research context
The guide records 1.6 mg with twice weekly source reference. This is educational source context, not an individual direction or a validated Aervyn protocol.
Evidence context
Grade B
Grade B, moderate human evidence. Regulatory reference in the guide: authorised in some jurisdictions and variable elsewhere. Evidence and legal status remain indication, product and market specific.
Limitations
Findings for a named medicine, vial, nasal preparation, oral product or controlled trial cannot be transferred automatically to an Aervyn pen. Long-term safety, formulation equivalence and individual response may remain uncertain.
Research focus
T-cell · Toll-like-receptor and immune-modulation research
Considerations
Evidence, suitability, interactions and longer-term effects vary by compound. Product information is educational and is not a personal recommendation or administration protocol.
Potential side effects
Injection-site reaction, Fatigue, Headache, Flu-like symptoms, Nausea.
PROCESS01 02 03 04
From discovery to pen
Discovered in biology
Many peptide sequences originate from signals already found in biology. Researchers first identify the sequence and investigate its function.
Synthesised in the laboratory
Chemists reconstruct the amino-acid sequence using controlled peptide-synthesis processes and characterise the resulting compound.
Checked against specifications
Identity, purity and other batch-specific quality attributes should be assessed against documented specifications before release.
Prepared in the pen format
The compound is prepared to the stated concentration and filled into the Aervyn 3 mL pen presentation for consistent volume arithmetic.
QUALITY, VERIFIED
Evidence behind every batch.
1
Independent labs
Analysed by accredited third-party laboratories, never self-reported.
2
>99% batch purity
HPLC quantifies purity and mass spectrometry confirms peptide identity.
3
Full traceability
Every peptide carries a unique identifier tied to its Certificate of Analysis.
GO DEEPER
Explore the science by product.
Open individual compounds to understand their mechanism, research context, evidence strength and limitations.
Explore productsRESPONSIBLE INFORMATION
Educational content, not an individual direction.
This page explains research concepts and arithmetic. It does not prescribe, diagnose, establish suitability or recommend an amount, frequency, cycle or administration method. Evidence and regulatory status differ by compound, indication, presentation and market.